Entrada Therapeutics Inc
TRDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$267.47M
Close$
$5.74
5.1% downside
Current Fair Value
5.1% downsideOvervalued by 5.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $267.47 Million |
|---|---|
| Enterprise Value | $241.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | -0.26 |
| Outstanding Shares | 41,836,275 |
Return
| Return on Equity | -61.33% |
|---|---|
| Return on Assets | -49.51% |
| Return on Invested Capital | -55.41% |
Valuation & Multiples
| P/E Ratio | -1.72 |
|---|---|
| PEG | -1.34 |
| Price to Sales | - |
| Price to Book Ratio | 1.01 |
| Enterprise Value to Revenue | 42.01 |
| Enterprise Value to EBIT | -1.38 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$2.92 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
$2.23 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.13%▼ 60.77% |
|---|---|
| Total Invested | $384,533▼ 99.88% |
| Investors Holding | 8▼ 111.00% |
ESG Score
No data